Product Spotlight

By: Steve Barrett
Sunday, May 1, 2016
Specialty: 

Image courtesy of Sherwin-Williams

Paint Shield

The CDC estimates that one in 25 patients in a U.S. hospital on any given day has a healthcare-associated infection (HAI), and most HAIs take place outside the ICU.

Sherwin-Williams has introduced Paint Shield, a paint that kills more than 99.9 percent of bacteria such as MRSA, E. coli, Staph and Enterobacter aerogenes after two hours of exposure on surfaces coated with the product.

Paint Shield can be a valuable tool in healthcare organizations’ efforts to limit the spread of bacteria that frequently cause HAIs, Sherwin-Williams says in a news release about the EPA-registered microbicidal paint.

So long as surface integrity is maintained, Paint Shield can remain effective for as long as four years, according to the company, and its bacteria-killing properties remain after repeated contamination.


Fenix Continence Restoration System

PS-Fenix Ring 250
Image courtesy of Torax Medical

Attempts to gauge the incidence of fecal incontinence are stymied by unwillingness on the part of patients to divulge symptoms to healthcare providers. The reported incidence of 2–3 percent is considered low.

Fecal incontinence can be socially debilitating, however, spurring a barrage of medical and surgical options. The FDA recently approved the Fenix Continence Restoration System for surgical treatment of the condition among patients who have not had success with, or are not candidates for, other approaches.

The implant, made by Torax Medical Inc., is composed of a band of titanium beads that have magnetic cores. Leveraging that magnetic attraction, the system augments the anal sphincter and creates a barrier against unintended escape of fecal matter. The barrier is broken for voluntary passage of fecal matter but is promptly restored, according to Torax Medical.

In a study of 35 adults, episodes of fecal incontinence fell by at least half for 62.9 percent of participants 12 months after the procedure.


DigniCap Intelligent Scalp Cooling System

PS-Digni Cap 250
Image courtesy of Dignitana

Dignitana Inc. has gained FDA approval for its DigniCap Intelligent Scalp Cooling System, designed to limit hair loss related to chemotherapy used in treating breast cancer.

While hair loss from breast cancer treatment is not typically permanent, it is among the psychologically painful side effects.

The DigniCap system lowers scalp temperature to restrict the flow of blood to the scalp. As a result, the amount of chemotherapy reaching hair cells is reduced, according to Dignitana. The system also slows hair cells’ metabolism, and the process increases the chance that the cells will survive treatment.

To enhance comfort, the silicone cap is initially at room temperature. The temperature drops as coolant circulates, but a sensor prevents the cap from falling below freezing.

A clinical trial found use of the DigniCap allowed 70 percent of patients with early-stage breast cancer to retain at least half of their hair.